The Latest Breaking News from Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Reveals Lower Net Loss For Q4 And Full Year 2021

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) reported Tuesday financial results for the fourth quarter and full year ended December 31, 2021.

Benzinga · Mar 1, 2022

Zynerba Pharmaceuticals Completes Enrollment For CBD Transdermal Trial For 22q Deletion Syndrome

Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc.

Benzinga · Feb 28, 2022

Zynerba Pharmaceuticals Names New CLO & Corporate Secretary

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary.

Benzinga · Feb 15, 2022